Bliss GVS Pharma Limited (BOM:506197)

Market Cap	64.16B +294.7%
Revenue (ttm)	10.05B +20.6%
Net Income	1.36B +27.7%
EPS	12.62 +25.3%
Shares Out	106.33M
PE Ratio	47.81
Forward PE	n/a
Dividend	2.00 (0.33%)
Ex-Dividend Date	Jul 8, 2026

Volume	27,523
Open	633.00
Previous Close	630.80
Day's Range	599.30 - 633.00
52-Week Range	118.35 - 744.75
Beta	1.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Bliss GVS Pharma

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is b...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,033
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506197

Financial Performance

In fiscal year 2026, Bliss GVS Pharma's revenue was 9.27 billion, an increase of 14.50% compared to the previous year's 8.10 billion. Earnings were 1.29 billion, an increase of 53.18%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 6, 2026

Data Sources Report a data error